The purpose of this study is to determine whether a new medical technology can help reduce post-operative total knee or hip pain when combined with a Cognitive-Behavioral intervention (CBI).

This new medical technology, is called transcranial direct current stimulation (tDCS), it uses a very small amount of electricity to temporarily stimulate specific areas of the brain thought to be involved in pain reduction. The electrical current passes through the skin, scalp, hair, and skull and requires no additional medication, sedation, or needles.

This study will investigate the effects of tDCS, the Cognitive-Behavioral (CB) intervention and their combination on pain among veterans following total knee arthroplasty (TKA) or total hip arthroplasty (THA). You may benefit in the form of decreased pain and opioid requirements following your knee or hip replacement surgery. However, benefit is only likely if you are randomized to one of the 3 (out of 4) groups.

This study hopes to determine the effects of these interventions and their combined effect on post-operative pain, opioid use and functioning during the 48-hour post-operative period following a total knee or hip replacement.

Phenylketonuria (PKU) is an autosomal recessive inborn error of L-phenylalanine (L-Phe) metabolism which is caused by deleterious variants in the gene coding for the phenylalanine hydroxylase (PAH) enzyme. The PAH enzyme catalyses the conversion of phenylalanine (Phe) to tyrosine (Tyr), a precursor of several neurotransmitters, hormones, skin, hair, and eye pigments. Elevated concentration of Phe and secondary metabolites and lower Tyr concentration in blood and in brain cause degenerative neuropathology, neurological symptoms, and intellectual deficits, together with poorly or non-pigmented skin and hair, and musty odor which are characteristic in untreated patients with PKU (1, 2).
This Phase 1/Phase 2 study is designed to assess the safety and efficacy of escalating doses of SAR444836 treatment in participants with PKU. The data collected will help to evaluate whether this adeno-associated virus (AAV) vector which delivers the functional human PAH gene into hepatocytes is effective in the treatment of PKU disease. The expression of PAH gene in hepatocytes is expected to provide steady low plasma levels of Phe similar to those observed in healthy individuals, preventing marked fluctuations caused by normal dietary protein intake.
The study is divided into 2 parts including a dose escalation phase (Stage 1A) and a dose expansion phase (Stage 1B).

The purpose of this study is to evaluate investigational treatments (study drug) in people with gastroesophageal adenocarcinoma that has progressed (become worse) after at least 2 prior treatments.

The goal is to determine the optimal dose level, safety, and tolerability for the study drug MK2870-015. This is a phase 3 study; MK2870-015 is not FDA approved by the U.S. Food and Drug Administration (FDA). Treatment for this study may be up to 3 years. The procedures include taking study drug intravenously, blood and urine samples, MUGA scans and CT scans. Risks include diarrhea, nausea, vomiting, hair loss, weight loss, high blood sugar, and sore throat. You may or may not receive a direct benefit from participating in this trial, however, information learned from the trial may help other people in the future.

The purpose of this study is to determine what kind of chemotherapy to recommend to patients based on the presence or absence of circulating tumor DNA (ctDNA) after surgery for colon cancer? ctDNA, or circulating tumor DNA, is DNA that has been released from tumor cells into your bloodstream. This DNA can be measured using a blood test.

This study seeks to find if this approach is better or worse than standard of care for colon cancer.

Treatment and follow up for this study may be up to 8 years. The procedures include blood samples, tissue samples, and chemotherapy. Risks include diarrhea, nausea, vomiting, hair loss, mouth sores, loss of appetite, tingling or pain in hands/feet/arms/legs, and anemia. You may or may not receive a direct benefit from participating in this trial, however, information learned from the trial may help other people in the future.